{"id":2259,"date":"2021-10-06T08:46:02","date_gmt":"2021-10-06T12:46:02","guid":{"rendered":"https:\/\/lifescivoice.com\/?p=2259"},"modified":"2021-10-06T08:46:03","modified_gmt":"2021-10-06T12:46:03","slug":"astrazeneca-partners-with-imperials-vaxequity-to-bolster-its-self-amplifying-rna-based-drugs-pipeline","status":"publish","type":"post","link":"https:\/\/lifescivoice.com\/astrazeneca-partners-with-imperials-vaxequity-to-bolster-its-self-amplifying-rna-based-drugs-pipeline\/","title":{"rendered":"AstraZeneca partners with Imperial\u2019s VaxEquity to bolster its self-amplifying RNA based drugs pipeline"},"content":{"rendered":"\n<p>AstraZeneca has inked a deal with VaxEquity, a firm producing experimental COVID-19 vaccine of U.K.\u2019s Imperial College, to develop and market drugs for other disease areas that are based on self-amplifying RNA technology.<\/p>\n\n\n\n<p>In consonance with the deal, VaxEquity, which is a startup by Robin Shattock- an Imperial College\u2019s vaccinologist- could receive $195 million as a milestone payment along with the royalties on approved drugs. The company has received upfront equity investments from AstraZeneca and Morningside Ventures.<\/p>\n\n\n\n<p>Mene Pangalos, AstraZeneca\u2019s research chief, stated, &#8220;This collaboration with VaxEquity adds a promising new platform to our drug discovery toolbox.&#8221;&nbsp;<\/p>\n\n\n\n<p>AstraZeneca, the British-Swedish biopharma, is already producing adenoviral vector vaccine for COVID-19 and now focusing to accentuate the potential of self-amplifying RNA technology used in various other therapies beyond COVID-19.<\/p>\n\n\n\n<p>The saRNA technology is analogous to the mRNA one used by Pfizer\/BioNTech and Moderna in their COVID vaccines, except the fact that it not only encodes information of the host cell to make coronavirus-related protein, but also replicates the RNA containing that information a number of times, hence making the doses smaller and cheaper.&nbsp;<\/p>\n\n\n\n<p>The giant biopharma, under the deal, is open to collaborate on 26 drugs targeting other therapeutic areas like cancer and other rare genetic diseases.<\/p>\n\n\n\n<p>COVID-19 vaccine produced by VaxEquity is being overhauled to produce more consistent and efficient immune response particularly keeping in view the future coronavirus variants.<\/p>\n\n\n\n<p>Safety and efficacy data obtained from the initial trials of the vaccine are encouraging, as said by Shattock, and the results of phase I trials of the refined vaccine are expected to be available by the first quarter of the coming year.&nbsp;&nbsp;<\/p>\n\n\n\n<p>&#8220;The reason we were slower was because we were coming from an academic setting,&#8221; Shattock said, &#8220;If we had this relationship (with AstraZeneca) at the beginning of 2020, we might have been faster.&#8221;<\/p>\n\n\n\n<p>The U.S. based firms Gritstone Bio and Arcturus are also on the way of developing COVID-19 vaccines based on saRNA technology. &nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca has inked a deal with VaxEquity, a firm producing experimental COVID-19 vaccine of U.K.\u2019s Imperial College, to develop and market drugs for other disease areas that are based on self-amplifying RNA technology. In consonance with the deal, VaxEquity, which is a startup by Robin Shattock- an Imperial College\u2019s vaccinologist- could receive $195 million as [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2260,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[304,548,205,549,550],"class_list":{"0":"post-2259","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-research-development","8":"tag-astrazeneca","9":"tag-imperial","10":"tag-mrna","11":"tag-rna-technology","12":"tag-vaxequity"},"_links":{"self":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/2259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/comments?post=2259"}],"version-history":[{"count":0,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/2259\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media\/2260"}],"wp:attachment":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media?parent=2259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/categories?post=2259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/tags?post=2259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}